Vanta Bioscience
25.29
0.00(0.00%)
Market Cap₹18.00 Cr
PE Ratio168.60
IndustryHealthcare
Company Performance:
1D0.00%
1M+9.39%
6M+13.66%
1Y-4.24%
5Y-84.30%
View Company Insightsright
More news about Vanta Bioscience
01Aug 25
Vanta Bioscience Reports Significant Losses for FY2025 Amid Revenue Decline
Vanta Bioscience Limited, a preclinical contract research organization, reported a substantial net loss for FY2025. Standalone net loss was Rs 265.95 lakh, compared to a profit of Rs 5.11 lakh in the previous year. Revenue from operations declined by 86.80% to Rs 112.74 lakh. Consolidated results showed a net loss of Rs 477.49 lakh, with revenue falling by 79.80% to Rs 196.36 lakh. The company faced operational challenges, including delays in consolidating financial results due to late receipt of accounts from an associate company. Despite financial difficulties, total assets increased by 2.52% to Rs 52.90 crore, while current liabilities rose by 39.22% to Rs 14.20 crore.
 no imag found
Vanta Bioscience
25.29
0.0
(0.0%)
1 Year Returns:-4.24%
Industry Peers
Syngene International
411.60
(-2.63%)
Indegene
493.70
(+0.38%)
Suven Life Sciences
317.10
(-0.70%)
Vimta Labs
537.95
(-2.73%)
Take Solutions
24.85
(+0.28%)
Bilcare
62.25
(+0.37%)
Adeshwar Meditex
16.00
(0.0%)
Vanta Bioscience
25.29
(0.0%)